478 related articles for article (PubMed ID: 21125340)
1. Therapeutically targeting the SUMOylation, Ubiquitination and Proteasome pathways as a novel anticancer strategy.
Driscoll JJ; Dechowdhury R
Target Oncol; 2010 Dec; 5(4):281-9. PubMed ID: 21125340
[TBL] [Abstract][Full Text] [Related]
2. Targeting the ubiquitin+proteasome system in solid tumors.
Driscoll JJ; Woodle ES
Semin Hematol; 2012 Jul; 49(3):277-83. PubMed ID: 22726552
[TBL] [Abstract][Full Text] [Related]
3. Targeting the ubiquitin-proteasome pathway: an emerging concept in cancer therapy.
Frezza M; Schmitt S; Dou QP
Curr Top Med Chem; 2011 Dec; 11(23):2888-905. PubMed ID: 21824109
[TBL] [Abstract][Full Text] [Related]
4. Overview of proteasome inhibitor-based anti-cancer therapies: perspective on bortezomib and second generation proteasome inhibitors versus future generation inhibitors of ubiquitin-proteasome system.
Dou QP; Zonder JA
Curr Cancer Drug Targets; 2014; 14(6):517-36. PubMed ID: 25092212
[TBL] [Abstract][Full Text] [Related]
5. The proteasome: a novel target for anticancer therapy.
Montagut C; Rovira A; Albanell J
Clin Transl Oncol; 2006 May; 8(5):313-7. PubMed ID: 16760005
[TBL] [Abstract][Full Text] [Related]
6. Ubiquitin-proteasome system as a target for anticancer treatment-an update.
Kim YJ; Lee Y; Shin H; Hwang S; Park J; Song EJ
Arch Pharm Res; 2023 Jul; 46(7):573-597. PubMed ID: 37541992
[TBL] [Abstract][Full Text] [Related]
7. Ubiquitin-proteasome system (UPS) as a target for anticancer treatment.
Park J; Cho J; Song EJ
Arch Pharm Res; 2020 Nov; 43(11):1144-1161. PubMed ID: 33165832
[TBL] [Abstract][Full Text] [Related]
8. Targeting the ubiquitin proteasome system in haematological malignancies.
Crawford LJ; Irvine AE
Blood Rev; 2013 Nov; 27(6):297-304. PubMed ID: 24183816
[TBL] [Abstract][Full Text] [Related]
9. Proteasome inhibitors: a therapeutic strategy for haematological malignancy.
Crawford LJ; Walker B; Irvine AE
Front Biosci; 2008 May; 13():4285-96. PubMed ID: 18508511
[TBL] [Abstract][Full Text] [Related]
10. Targeting the ubiquitin proteasome system: beyond proteasome inhibition.
Xolalpa W; Perez-Galan P; Rodríguez MS; Roué G
Curr Pharm Des; 2013; 19(22):4053-93. PubMed ID: 23181575
[TBL] [Abstract][Full Text] [Related]
11. Novel proteasome inhibitors to overcome bortezomib resistance.
Ruschak AM; Slassi M; Kay LE; Schimmer AD
J Natl Cancer Inst; 2011 Jul; 103(13):1007-17. PubMed ID: 21606441
[TBL] [Abstract][Full Text] [Related]
12. The ubiquitin+proteasome protein degradation pathway as a therapeutic strategy in the treatment of solid tumor malignancies.
Driscoll JJ; Minter A; Driscoll DA; Burris JK
Anticancer Agents Med Chem; 2011 Feb; 11(2):242-6. PubMed ID: 21355840
[TBL] [Abstract][Full Text] [Related]
13. Potent activity of carfilzomib, a novel, irreversible inhibitor of the ubiquitin-proteasome pathway, against preclinical models of multiple myeloma.
Kuhn DJ; Chen Q; Voorhees PM; Strader JS; Shenk KD; Sun CM; Demo SD; Bennett MK; van Leeuwen FW; Chanan-Khan AA; Orlowski RZ
Blood; 2007 Nov; 110(9):3281-90. PubMed ID: 17591945
[TBL] [Abstract][Full Text] [Related]
14. Bortezomib as the first proteasome inhibitor anticancer drug: current status and future perspectives.
Chen D; Frezza M; Schmitt S; Kanwar J; Dou QP
Curr Cancer Drug Targets; 2011 Mar; 11(3):239-53. PubMed ID: 21247388
[TBL] [Abstract][Full Text] [Related]
15. Proteasome inhibition in multiple myeloma: therapeutic implication.
Chauhan D; Hideshima T; Anderson KC
Annu Rev Pharmacol Toxicol; 2005; 45():465-76. PubMed ID: 15822185
[TBL] [Abstract][Full Text] [Related]
16. Immunoproteasome-selective and non-selective inhibitors: A promising approach for the treatment of multiple myeloma.
Ettari R; Zappalà M; Grasso S; Musolino C; Innao V; Allegra A
Pharmacol Ther; 2018 Feb; 182():176-192. PubMed ID: 28911826
[TBL] [Abstract][Full Text] [Related]
17. Targeting the UPS as therapy in multiple myeloma.
Chauhan D; Bianchi G; Anderson KC
BMC Biochem; 2008 Oct; 9 Suppl 1(Suppl 1):S1. PubMed ID: 19007431
[TBL] [Abstract][Full Text] [Related]
18. [Ubiquitin-proteasome pathway as a target for therapeutic strategies].
Staszczak M
Postepy Biochem; 2017; 63(4):287-303. PubMed ID: 29374430
[TBL] [Abstract][Full Text] [Related]
19. MDA-7/IL-24, a novel tumor suppressor/cytokine is ubiquitinated and regulated by the ubiquitin-proteasome system, and inhibition of MDA-7/IL-24 degradation enhances the antitumor activity.
Gopalan B; Shanker M; Scott A; Branch CD; Chada S; Ramesh R
Cancer Gene Ther; 2008 Jan; 15(1):1-8. PubMed ID: 17828282
[TBL] [Abstract][Full Text] [Related]
20. The ubiquitin-proteasome system: opportunities for therapeutic intervention in solid tumors.
Johnson DE
Endocr Relat Cancer; 2015 Feb; 22(1):T1-17. PubMed ID: 24659480
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
